Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Apr. 10, 2014 | Jun. 30, 2013 | |
Document Information [Line Items] | ' | ' | ' |
Entity Registrant Name | 'Neurotrope, Inc. | ' | ' |
Entity Central Index Key | '0001513856 | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Filer Category | 'Smaller Reporting Company | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 21,889,006 | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 31-Dec-13 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Entity Well-known Seasoned Issuer | 'No | ' | ' |
Entity Voluntary Filers | 'Yes | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Public Float | ' | ' | $0 |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
CURRENT ASSETS | ' | ' |
Cash and cash equivalents | $15,211,744 | $0 |
Prepaid expenses | 87,059 | 0 |
TOTAL CURRENT ASSETS | 15,298,803 | 0 |
TOTAL ASSETS | 15,298,803 | 0 |
CURRENT LIABILITIES | ' | ' |
Accounts payable and accrued expenses - related party | 251,779 | 1,240,636 |
Accounts payable and accrued expenses | 156,637 | 192,342 |
Advances from related party | 0 | 4,815 |
TOTAL CURRENT LIABILITIES | 408,416 | 1,437,793 |
Commitments and contingencies | ' | ' |
Convertible redeemable preferred stock, Series A, $.0001 par value, 50,000,000 shares authorized; 23,000,000 shares issued and outstanding (liquidation preference of $23,000,000 plus dividends accruable at 8% per annum of $1,023,616) | 19,943,572 | 0 |
SHAREHOLDERS' DEFICIT | ' | ' |
Common stock - 300,000,000 shares authorized, $.0001 par value; 21,690,406 issued and outstanding at December 31, 2012; 21,740,006 shares issued and outstanding at December 31, 2013 | 2,174 | 2,169 |
Additional paid-in capital | 3,974,007 | 0 |
Deficit accumulated during the development stage | -9,029,366 | -1,439,962 |
TOTAL SHAREHOLDERS' DEFICIT | -5,053,185 | -1,437,793 |
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | $15,298,803 | $0 |
CONSOLIDATED_BALANCE_SHEETS_Pa
CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Common stock, shares authorized | 300,000,000 | 300,000,000 |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares issued | 21,740,006 | 21,690,406 |
Common stock, shares outstanding | 21,740,006 | 21,690,406 |
Preferred stock, par value (in dollars per share) | $0.00 | $0.00 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred stock, shares issued | 23,000,000 | 0 |
Preferred stock, shares outstanding | 23,000,000 | 0 |
Preferred Stock, Liquidation Preference, Value (in dollars) | $23,000,000 | $0 |
Dividends Payable Percentage (in percentage) | 8.00% | 0.00% |
Dividends Payable (in dollars) | $1,023,616 | $0 |
CONSOLIDATED_STATEMENTS_OF_OPE
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 2 Months Ended | 12 Months Ended | 14 Months Ended |
Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | |
OPERATING EXPENSES: | ' | ' | ' |
Research and development - related party | $983,491 | $1,367,644 | $2,351,135 |
General and administrative - related party | 257,145 | 4,301,731 | 4,558,876 |
General and administrative | 197,157 | 1,921,407 | 2,118,564 |
TOTAL OPERATING EXPENSES | 1,437,793 | 7,590,782 | 9,028,575 |
OTHER INCOME: | ' | ' | ' |
Interest income | 0 | 1,378 | 1,378 |
Net loss before income taxes | -1,437,793 | -7,589,404 | -9,027,197 |
Provision for income taxes | 0 | 0 | 0 |
Net loss | ($1,437,793) | ($7,589,404) | ($9,027,197) |
PER SHARE DATA: | ' | ' | ' |
Basic and diluted loss per common share (in dollars per share) | ($0.07) | ($0.35) | ' |
Basic and diluted weighted average common shares outstanding (in shares) | 21,690,406 | 21,702,415 | ' |
CONSOLIDATED_STATEMENT_OF_CHAN
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' DEFICIT (USD $) | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit during Development Stage [Member] |
Balance at Oct. 31, 2012 | $0 | $269 | $0 | ($269) |
Balance (in shares) at Oct. 31, 2012 | ' | 2,690,400 | ' | ' |
Issuance of common stock | 0 | 1,900 | 0 | -1,900 |
Issuance of common stock, (in shares) | ' | 19,000,006 | ' | ' |
Net loss | -1,437,793 | ' | ' | -1,437,793 |
Balance at Dec. 31, 2012 | -1,437,793 | 2,169 | 0 | -1,439,962 |
Balance (in shares) at Dec. 31, 2012 | ' | 21,690,406 | ' | ' |
Issuance of common stock for consulting fees | 44,640 | 5 | 44,635 | ' |
Issuance of common stock for consulting fees (in shares) | ' | 49,600 | ' | ' |
Stock based compensation | 3,122,944 | ' | 3,122,944 | ' |
Issuance of common stock warrants | 806,428 | ' | 806,428 | ' |
Net loss | -7,589,404 | ' | 0 | -7,589,404 |
Balance at Dec. 31, 2013 | ($5,053,185) | $2,174 | $3,974,007 | ($9,029,366) |
Balance (in shares) at Dec. 31, 2013 | ' | 21,740,006 | ' | ' |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 2 Months Ended | 12 Months Ended | 14 Months Ended |
Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ' | ' | ' |
Net loss | ($1,437,793) | ($7,589,404) | ($9,027,197) |
Adjustments to reconcile net loss to net cash used by operating activities | ' | ' | ' |
Stock based compensation | 0 | 3,122,944 | 3,122,944 |
Consulting services paid by issuance of common stock | 0 | 44,640 | 44,640 |
Change in assets and liabilities | ' | ' | ' |
Increase in prepaid expenses | 0 | -87,059 | -87,059 |
(Decrease) increase in accounts payable and accrued expenses - related party | 1,240,636 | -988,857 | 251,779 |
(Decrease) increase in accounts payable and accrued expenses | 192,342 | -35,705 | 156,637 |
Total adjustments | 1,432,978 | 2,055,963 | 3,488,941 |
Net Cash Used by Operating Activities | -4,815 | -5,533,441 | -5,538,256 |
CASH FLOWS FROM FINANCING ACTIVITIES | ' | ' | ' |
Issuance of preferred stock, preferred stock warrants and common stock warrants net of transaction costs | 0 | 20,750,000 | 20,750,000 |
(Repayment of advances) advances from related party | 4,815 | -4,815 | 0 |
Net Cash Provided by Financing Activities | 4,815 | 20,745,185 | 20,750,000 |
NET INCREASE IN CASH | 0 | 15,211,744 | 15,211,744 |
CASH AT BEGINNING OF YEAR | 0 | 0 | 0 |
CASH AT END OF YEAR | $0 | $15,211,744 | $15,211,744 |
Organization_and_Nature_of_Pla
Organization and Nature of Planned Business: | 12 Months Ended |
Dec. 31, 2013 | |
GENERAL ORGANIZATION AND BUSINESS [Abstract] | ' |
Nature of Operations [Text Block] | ' |
Note 1 – Organization and Nature of Planned Business: | |
References in these notes to the consolidated financial statements to “Neurotrope, Inc.,” “we,” “us,” “our Company” refer to Neurotrope, Inc. and its consolidated subsidiary Neurotrope Biosciences, Inc. (“NBI”). NBI was incorporated in Delaware on October 31, 2012. NBI was formed to advance new diagnostic and therapeutic technologies in the field of neurodegenerative disease, primarily Alzheimer’s Disease. NBI plans to collaborate with the Blanchette Rockefeller Neurosciences Institute (“BRNI”), a related party, in this process. The exclusive rights to the licensed technology transferred to the Company on February 28, 2013 (see Note 4). | |
On August 23, 2013, a wholly owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013 (“Acquisition Sub”) merged (the “Reverse Merger”) with and into NBI. NBI was the surviving corporation in the Reverse Merger and became the Company’s wholly owned subsidiary. All of the outstanding NBI common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis. | |
The Merger is being accounted for as a reverse-merger and recapitalization with NBI as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the Merger are those of NBI and are recorded at the historical cost basis of NBI and the consolidated financial statements after completion of the Merger include the assets and liabilities of NBI and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and NBI from the closing date of the Merger. The stockholders’ equity section has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction on the basis of the 1:1 exchange ratio on the Merger date. | |
As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of NBI, and will continue the existing business operations of NBI as a publicly-traded company. | |
On February 28, 2013, NBI effected a stock split in which each of the 1,000 issued and outstanding shares of its common stock was converted into 19,000 shares of its common stock. | |
Contractual_Commitments
Contractual Commitments: | 12 Months Ended |
Dec. 31, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments Disclosure [Text Block] | ' |
Note 2 – Contractual Commitments: | |
From January 1, 2013 through February 28, 2013, the Company compensated its President under an independent contractor agreement at the rate of $20,833 per month (see Note 4). On February 25, 2013, the Company executed a four-year employment agreement, effective March 1, 2013, with its President. This agreement provides for an annual salary of $250,000 and annual bonus of $50,000, which shall increase to an annual salary of $300,000 and an annual bonus of $100,000 effective as of the later of (a) February 28, 2015 or (b) the closing by the Company of a Series B Preferred Stock financing as described in Note 4 below. | |
Effective February 28, 2013, the Company executed an agreement with Ramat Consulting Corp. (“Ramat”), a related party, for consulting services, including business development and marketing consulting, for a five-year period, subject to annual renewals thereafter. Ramat's annual fee is $50,000, payable in monthly installments of $4,167, plus pre-approved travel and other reimbursable expenses. Ramat is also entitled to an option, with a term of ten years, to purchase 300,000 shares of common stock of the Company at an exercise price of $1.00 per share. The option shall be deemed to have vested with respect to 20% of the shares as of February 28, 2013, and the balance shall vest on a daily basis over the four-year period beginning on February 28, 2013. An entity related to Ramat purchased one million shares of Series A preferred stock on the effective date of this agreement. | |
Effective June 2, 2013, the Company executed a consulting agreement with Medical Cash Management Solutions, LLC (“MCMS”) for services as the Company's Chief Financial Officer, on an independent contractor basis, through November 30, 2013 at a fee of $20,000 per month plus reimbursable expenses. This agreement is subject to renewal terms as agreed to by the parties. | |
On October 1, 2013, the Company canceled its agreement with MCMS and executed a four-year employment agreement, effective October 1, 2013, with its Chief Financial Officer. This agreement provides for an annual salary of $240,000 which shall increase to an annual salary of $275,000 beginning January 1, 2015. In addition, the agreement provides for a $35,000 bonus for year ended December 31, 2013, a $50,000 bonus for year ended December 31, 2014 and a targeted bonus of 50% of base salary for all subsequent years. In addition, on October 1, 2013 the Board granted a qualified stock option to the CFO under the Company’s 2013 Equity Incentive Plan to purchase 650,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.00 per share. These options vest 25% per year over four years, with accelerated vesting of 25% upon a termination without cause or for good reason. | |
Summary_of_Significant_Account
Summary of Significant Accounting Policies: | 12 Months Ended |
Dec. 31, 2013 | |
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] | ' |
Significant Accounting Policies [Text Block] | ' |
Note 3 - Summary of Significant Accounting Policies: | |
Development Stage: | |
The Company is considered to be a development stage company, as defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915-10, in that the Company is devoting substantially all of its efforts to establishing a new business where planned principal operations have commenced, but no revenues have been derived from these operations. | |
In addition, the Company’s licensed technology may not be ready for commercialization for several years, if at all. The Company expects to continue to incur losses at least until commercialization, because it anticipates that its expenditures on research and development and administrative activities will significantly exceed any potential revenues during the period. The Company cannot predict when, if ever, it will become profitable. | |
Use of Estimates: | |
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
Cash and Cash Equivalents: | |
The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2013, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. | |
Research and Development Costs: | |
All research and development costs, including costs to maintain or expand the patent portfolio which do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2013 and 2012. | |
Income Taxes: | |
Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carry forwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carry forwards, which will either be taxable or deductible when the related assets, liabilities or carry forwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. | |
Uncertain Tax Positions: | |
The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. | |
The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through December 31, 2012. The Company has not yet filed tax returns for the year ended December 31, 2013. | |
In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed. | |
Risks and Uncertainties: | |
The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation, including but not limited to the United States FDA drug and device approval processes. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks including the potential for business failure. | |
Stock Compensation: | |
The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. | |
Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model. | |
Earnings per Share: | |
Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible stock, subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of December 31, 2013 and 2012. At December 31, 2013 and 2012, respectively, approximately 31.5 million and 0 shares underlying the convertible debentures, options and warrants were anti-dilutive. | |
Related_Party_Transactions
Related Party Transactions: | 12 Months Ended |
Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
Note 4 – Related Party Transactions: | |
The Company incurred consulting fees of $41,667 to its President during the period from January 1, 2013 to February 28, 2013 (see Note 3). | |
One director of the Company, until November 8, 2013, is also a director of BRNI. A second director of the Company is both the president and a director of BRNI. Both of these current and former directors are stockholders of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”) that owns 41.5% of the Company's outstanding common stock. | |
Effective October 31, 2012, the Company executed a Technology License and Services Agreement with BRNI, a related party, and two entities affiliated with BRNI (the “Agreement”). Under the terms of the Agreement, BRNI provides research services and grants the Company the exclusive and nontransferable license right to certain patent and intellectual property which became effective upon the Company's completion of a Series A Preferred Stock financing generating net proceeds to the Company of at least $8,000,000 on February 28, 2013. The Agreement terminates on the latter of the date (i) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (ii) the last of the intellectual property enters the public domain. | |
The research services provided under the Agreement commenced on April 2, 2012. The Agreement requires the Company to reimburse BRNI for services rendered (the “Services Reimbursement”) on a pro-rated, thirty month basis, with respect to the period of time elapsed from April 2, 2012 through the date of the Series A Preferred Stock financing on February 28, 2013. BRNI invoiced the Company $1,198,696 for service reimbursements through December 31, 2012 and an additional $266,666 from January 1, 2013 to February 28, 2013. | |
The Agreement may require the Company to enter into scope of work agreements with BRNI. The Company shall not engage any other person other than BRNI to perform research or development services or other related scientific assistance without prior written consent of BRNI with such consent not unreasonably withheld. BRNI and Neurotrope may agree to have a third party provide services identical or similar to such services to Neurotrope in the case where BRNI is demonstrably unable to do so or such third party is demonstrably in a superior position to do so. | |
In addition to the fees under the services reimbursement and scope of work agreements, the Agreement requires the Company to pay BRNI a “Fixed Research Fee”, commencing the date that the Company completes a Series B Preferred Stock financing resulting in net proceeds of at least $25,000,000 (the “Series B Financing”). The fixed research fee is (i) a pro- rata amount of $1,000,000 in the year the Company completes such financing (ii) $1,000,000 per year for five calendar years subsequent to such financing and (iii) an annual fixed research fee in an amount to be negotiated and agreed upon no later than 90 days prior to the end of the fifth calendar year following the completion of such financing to be paid with respect to each remaining calendar year during the term of the Agreement. The Company had not completed this Series B Financing at December 31, 2013 (see Note 7) and, accordingly, no such fee was due as of that date. | |
The Agreement also requires the payment of royalties ranging between 2% and 5% of the Company’s revenues generated from the licensed patents and other intellectual property, dependent upon the percentage ownership that NRVI holds in the Company. Under the Agreement, the Company is required to prepay royalty fees at a rate of 5% of all investor funds raised in the Series A or Series B Preferred Stock financings or any subsequent rounds of financing prior to a public offering, less commissions. On March 25, 2013, the Company prepaid $409,549 in royalties under the Agreement and paid the remainder due of $60,349 in July 2013 relating to the May 7, 2013 Series A preferred stock financing. On August 29, 2013, the Company paid $520,252 in prepaid royalties relating to the August 23, 2013 Series A preferred stock financing. On October 4, 2013, the Company paid $48,600 in prepaid royalties relating to the Series A preferred stock financing. These royalties are expensed in “general and administrative expenses – related party” in the statement of operations. | |
On August 21, 2013, the Company and BRNI amended the Agreement to clarify certain provisions. | |
On August 22, 2013, the Board of Directors agreed to compensate its Chairman $9,000 per month for ongoing services to the Company relating to product development and negotiation of agreements with BRNI and outside contractors and consultants. | |
Effective August 28, 2013, the Company signed a statement of work (“SOW”) with BRNI pursuant to its licensing agreement (noted above) whereby the Company has contracted for the further development of its AD diagnostic product. Pursuant to the SOW, the Company is obligated to pay BRNI a total of $1,645,470 in 12 equal monthly installments of $137,123, payable on the first business day of each month. These payments are for operating expenses associated with BRNI’s diagnostic laboratories. Operating expenses that are incurred in excess of this total amount are the responsibility of BRNI unless prior approval is obtained from the Company. The SOW may be extended if BRNI provides the Company with two months advanced notice that the SOW objectives are not met within the initial 12 month period. The Company will agree to continue funding the SOW at the same monthly rate for a period not to exceed an additional six (6) months to conclude the first anticipated clinical trial for the AD diagnostic product. In addition, the Company has agreed to pay an estimated $877,300 in external costs to complete the first clinical trial. | |
Effective November 13, 2013, the Company agreed to an SOW with BRNI pursuant to its licensing agreement (noted above) whereby the Company has contracted for the further development of its AD therapeutic product. Pursuant to the SOW, the Company paid BRNI $251,939 for related personnel and research services. The Company has expensed this entire amount in year ended December 31, 2013. | |
Income_Taxes
Income Taxes: | 12 Months Ended |
Dec. 31, 2013 | |
INCOME TAXES [Abstract] | ' |
Income Tax Disclosure [Text Block] | ' |
Note 5 – Income Taxes: | |
The Company incurred a net operating loss for income tax purposes of $9,027,197 for the period from October 31, 2012 (inception) through December 31, 2013. This amount is available for carry forward for use in offsetting taxable income of future years through 2032. The net operating loss carry forward resulted in a deferred tax asset of $3,069,247 at December 31, 2013, which is reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes. | |
Availability and utilization of the net operating loss carry forward may be limited due to changes in control. | |
Common_Stock
Common Stock: | 12 Months Ended |
Dec. 31, 2013 | |
STOCKHOLDERS' EQUITY [Abstract] | ' |
Stockholders Equity Note Disclosure [Text Block] | ' |
Note 6 – Common Stock: | |
On February 28, 2013, NBI amended and restated its Certificate of Incorporation to authorize 45,000,000 common shares at a par value of $0.01. On that date, the Company issued 19,000,000 common shares. This recapitalization has been presented retroactively in the accompanying financial statements. | |
On June 20, 2013, BlueFlash Communications, Inc., a Florida corporation (“BlueFlash”), entered into an Agreement and Plan of Merger (the “Plan of Merger”) with Neurotrope, Inc., its wholly owned Nevada subsidiary, pursuant to which BlueFlash would merge with and into Neurotrope (the “Reincorporation Merger”). The Plan of Merger was amended by the Amendment to Agreement and Plan of Merger between the parties, dated July 10, 2013 (the “Amendment”). The purpose of the Merger was to re-domicile BlueFlash from Florida to Nevada, and to effect a name change and recapitalization as described below. | |
On August 5, 2013, Articles of Merger were filed with both the Secretary of State of the State of Nevada and the Secretary of State of the State of Florida, pursuant to which the Reincorporation Merger was effective as of August 9, 2013. Upon effectiveness of the Merger, Neurotrope, Inc.’s Articles of Incorporation and Neurotrope, Inc.’s Amended and Restated Bylaws became the Articles of Incorporation and Amended and Restated Bylaws of the registrant. | |
Neurotrope, Inc., has an authorized share capital of 300,000,000 shares of common stock, par value $0.0001 per share (“Neurotrope Common Stock”) and 50,000,000 shares of “blank check” preferred stock, par value $0.0001 per share. Prior to the Reincorporation Merger, Neurotrope, Inc. had 100 shares of its Neurotrope Common Stock outstanding, held by BlueFlash, and therefore was a wholly-owned subsidiary of BlueFlash. Prior to the Merger, Neurotrope, Inc. had no assets, liabilities or business. | |
Pursuant to the Plan of Merger, among other things, (i) each share of common stock of BlueFlash, $0.0001 par value per share (“BlueFlash Common Stock”) was automatically converted into 2.242 shares of Neurotrope Common Stock. | |
On August 21, 2013, the NBI amended its articles of incorporation to increase its authorized shares of common stock from 45,000,000 shares to 57,000,000 shares. | |
On August 23, 2013, the Reverse Merger occurred as described in Note 1 above, and all of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis. | |
In connection with the Reverse Merger and pursuant to a Split-Off Agreement, Neurotrope, Inc. transferred its pre-Reverse Merger business to Marissa Watson, its pre-Reverse Merger majority stockholder, in exchange for the surrender by her and cancellation of 20,178,000 shares of Neurotrope, Inc. common stock. | |
Preferred_Stock
Preferred Stock: | 12 Months Ended |
Dec. 31, 2013 | |
Equity [Abstract] | ' |
Preferred Stock [Text Block] | ' |
Note 7 – Preferred Stock: | |
Through a private placement, NBI issued 9,073,300 preferred shares at $1 per share on that date, resulting in gross proceeds of $9,073,300. In connection with the February 28, 2013 closing of the private placement, the Company was required to pay the placement agent, Allied Beacon Partners, Inc., a cash fee equal to the sum of (a) 10% of the proceeds received from purchasers sourced by Allied Beacon Partners, Inc. and (b) 5% of the proceeds received from purchasers sourced by the Company. No fee was payable on proceeds received from purchasers who were already stockholders of the Company. The total cash fee that the Company was required to pay in connection with this closing was $882,330. The Company was also obligated to issue to Allied Beacon Partners, Inc. warrants for the purchase of common stock and Series A preferred stock of the Company in connection with the closing. The aggregate number of shares subject to such warrants was the sum of 10% of the number of shares purchased by purchasers sourced by Allied Beacon Partners, Inc. and (b) 5% of the number of shares purchased by purchasers sourced by the Company. No warrants were earned on proceeds received from purchasers who were already stockholders of the Company. | |
On May 17, 2013, NBI issued an additional 1,313,325 shares of Series A preferred stock at $1.00 per share, resulting in gross proceeds of $1,313,325, on which NBI paid the placement agent cash of $131,332 and warrant compensation under the same terms as applied with respect to the February 28, 2013 closing. | |
The total number of shares subject to warrants that NBI was required to issue in connection with the February and May 2013 closings was 988,663, consisting of 480,320 shares of common stock and 508,343 shares of Series A preferred stock. These warrants have a term of ten years. The strike price for the common stock warrants is $0.01 per share and the strike price for the Series A preferred stock warrants is $1.00 per share. | |
On August 23, 2013, NBI closed a private placement of 11,533,375 additional shares of its Series A preferred stock, for a purchase price of $1.00 per share, for aggregate gross proceeds of $11,533,375 (before deducting placement agent fees and expenses of the offering of $1,103,338). All of the 21,920,000 outstanding shares of NBI Series A preferred stock were converted into shares of Neurotrope Inc. Series A convertible preferred stock (the “Series A Preferred Stock”) on a one-for-one basis in the Reverse Merger. This additional financing was in conjunction with the Company’s merger with a publicly reporting shell company (See Note 1 above). | |
On October 4, 2013, the Company completed its Series A preferred stock offering through a private placement of 1,080,000 shares of its Series A preferred stock, for a purchase price of $1.00 per share, for aggregate gross proceeds of $1,080,000 (before deducting placement agent fees and expenses of the offering). As a result of the foregoing, the placement agent was paid an aggregate commission of $108,000 and was issued Agent Warrants to purchase 108,000 shares of the Company’s Series A preferred stock. | |
The Company agreed to pay the placement agent in the offering a cash commission of 10% of the gross funds raised from investors in the private placement offering (“PPO”). In addition, the placement agent received (a) for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 2.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 10% of the number of shares of Series A preferred stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the “Agent Warrants”). As a result of the foregoing aggregate placements, the placement agent was issued Agent Warrants to purchase 900,000 shares of the Company’s Common Stock and 1,325,000 shares of the Company’s Series A preferred stock. (See Note 8.) | |
The Series A preferred stock ranks senior with respect to liquidation preference and dividend rights to the common stock and any other class or series of stock that the Company may issue. The Series A preferred stock accrues a dividend at an annual rate of $0.08 per share, when and if declared by the Board of Directors of the Company. No dividends have been declared on the Series A preferred stock. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of our affairs or similar event, a holder of Series A preferred stock will be entitled to be paid, before any distribution or payment may be made to any holders of common stock or other class or series of stock, the liquidation amount (which shall equal $1.00 per share) and the amount of any accrued and unpaid dividends as of such distribution or payment date. Each share of Series A preferred stock is convertible into common stock at the option of the stockholder at a price of $1.00 per share, subject to adjustment. The Series A shares are subject to mandatory conversion upon the vote of holders of a majority of the outstanding shares of Series A preferred stock at any given time, or upon the closing of a sale of common stock to the public at a price of at least $5.00 per share (subject to adjustment in the case of certain events) in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in net proceeds to the Company of at least $30,000,000.The holders of Series A preferred stock are entitled to a class vote on certain Company actions, have the right to elect one of five members of the Company board of directors and have a right of first offer to purchase their pro rata share of equity securities issued by the Company in the future, in addition to certain additional rights and privileges as set forth in the Amended and Restated Certificate of Incorporation and in certain agreements between the Company and the holders thereof. | |
On August 21, 2013, NBI increased its authorized shares of preferred stock to 50,000,000 shares. As a result, the Company had a sufficient number of preferred shares to close the August 23, 2013 private placement. | |
Warrants
Warrants: | 12 Months Ended |
Dec. 31, 2013 | |
Warrants and Rights Note Disclosure [Abstract] | ' |
Warrants And Rights Note Disclosure [Text Block] | ' |
Note 8 – Warrants: | |
During the twelve months ended December 31, 2013, in conjunction with the Series A preferred stock financing (see Note 7), the Company issued warrants for 2,225,000 underlying shares, consisting of warrants for 900,000 underlying shares of common stock and warrants for 1,325,000 underlying shares of Series A preferred stock to the placement agents. Both warrants have a term of ten years. The strike price for the common stock warrants is $0.01 per share and the strike price for the Series A preferred stock warrants is $1.00 per share. | |
The 2,225,000 warrants issued during the twelve months ended December 31, 2013 were valued using the Black-Scholes option pricing model. The following weighted average assumptions were used for these warrants; risk free interest rates of 2.70%; expected dividend yield of 0%; expected term of 10 years and expected volatility of 105.5%. The weighted average remaining life of these warrants at December 31, 2013 was assumed to be 10 years. The total calculated fair value of these warrants as of December 31, 2013 is $2,020,813. | |
Of the $2,020,813 total fair value of warrants issued during the twelve months ended December 31, 2013, $806,428 has decreased Preferred Stock and increased paid-in-capital in the balance sheet and $1,214,385 has been recorded as an increase and decrease to preferred stock. | |
Stock_Options
Stock Options: | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] | ' | |||||||
Stock Option Note Disclosure [Text Block] | ' | |||||||
Note 9 – Stock Options: | ||||||||
Before the Reverse Merger, our Board of Directors adopted, and our stockholders approved, our 2013 Equity Incentive Plan (the “2013 Plan”), which provides for the issuance of incentive awards of up to 7,000,000 shares of the Company’s common stock to officers, key employees, consultants and directors. Upon the closing of the Reverse Merger, options to purchase an aggregate of 5,154,404 shares of the Company’s common stock were issued. Of these options: 1. 3,500,000 options were issued to founding stockholders and 54,404 were granted to a consultant, each with a term of ten years, exercisable at $1.75 per common share, 100% of these options vested on date of grant; 2. 1,050,000 options were issued to four directors (or their affiliates) and 250,000 to a consultant with a term of ten years, exercisable at $1.00 per common share, which vest 20% per year for each of five years after the date of grant, and; 3. 300,000 options were granted to a consultant with a term of ten years, exercisable at $1.00 per common share which vested 20% on date of grant and vest 20% per year over the next four years. These options were issued in conversion of options issued by NBI on February 28, 2013. | ||||||||
A summary of the Company’s stock option activity from inception to December 31, 2013 is as follows: | ||||||||
Weighted-Average | ||||||||
Options Outstanding | Exercise Price | |||||||
Outstanding at December 31, 2012 | 0 | |||||||
Options granted | 6,489,404 | $ | 1.47 | |||||
Options forfeited | -239,452 | $ | -1 | |||||
Options exercised | 0 | 0 | ||||||
Outstanding at December 31, 2013 | 6,249,952 | $ | 1.48 | |||||
Options exercisable | 3,764,733 | $ | 1.71 | |||||
The weighted-average remaining contractual term of options exercisable and outstanding at December 31, 2013 was approximately 9.64 and 9.68 years, respectively. | ||||||||
The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. | ||||||||
The fair value of stock options issued for the twelve months ended December 31, 2013 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Volatility 104.7%; Risk-free interest rate 2.71%; weighted average grant date fair value of $0.84 per common share. | ||||||||
The total stock option-based compensation recorded as operating expense was approximately $3.1 million for the twelve months ended December 31, 2013 and from inception to December 31, 2013. Approximately $0.2 million of the expense is classified as research and development and the remaining approximately $2.9 million of stock option-based compensation expense was classified as general and administrative expense. | ||||||||
As of December 31, 2013 and 2012, there was approximately $2.6 million and $0, respectively, of unrecognized compensation cost related to non-vested options under the plans. | ||||||||
Common_and_Preferred_Stock_Res
Common and Preferred Stock Reserved for Future Issuances: | 12 Months Ended | |||||
Dec. 31, 2013 | ||||||
Common And Preferred Stock Reserved For Future Issuances [Abstract] | ' | |||||
Common And Preferred Stock Reserved For Future Issuances [Text Block] | ' | |||||
Note 10 – Common and Preferred Stock Reserved for Future Issuances: | ||||||
Common stock and preferred stock reserved for future issuances consisted of the following at December 31, 2013: | ||||||
Common Stock | Preferred Stock | |||||
Reserved | Reserved | |||||
Common stock warrants outstanding | 900,000 | |||||
Preferred stock warrants outstanding | 1,217,000 | 1,217,000 | ||||
Common stock options outstanding | 6,249,952 | 0 | ||||
Conversion of Series A preferred stock | 23,000,000 | 0 | ||||
Total | 31,366,952 | 1,217,000 | ||||
Subsequent_Events
Subsequent Events: | 12 Months Ended |
Dec. 31, 2013 | |
SUBSEQUENT EVENTS [Abstract] | ' |
Subsequent Events [Text Block] | ' |
Note 11 – Subsequent Events: | |
The Company’s management has evaluated the effects of events occurring through April 15, 2014, the date these financial statements were available to be issued. | |
On January 2, 2014, the Company executed a one-year employment letter which is renewable annually, with NBI’s Vice President – Regulatory Affairs. This agreement provides for an annual salary of $195,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the offer letter provides for a discretionary bonus of up to 20% of base salary for all years. In addition, on January 23, 2014, the Company’s Board of Directors granted a qualified stock option to its VP – Regulatory Affairs under the Company’s 2013 Equity Incentive Plan to purchase 75,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. These options vest 20% per year over five years. | |
On January 16, 2014, the Company executed a four-year employment letter, with NBI’s Vice President – Commercial Operations. This agreement provides for an annual salary of $210,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the offer letter provides for a discretionary bonus of up to 35% of base salary for all years. In addition, on January 23, 2014, the Company’s Board of Directors granted a qualified stock option to its VP – Commercial Operations under the Company’s 2013 Equity Incentive Plan to purchase 100,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. These options vest 20% per year over five years. | |
On January 22, 2014, the Company executed a four-year employment agreement, with NBI’s Vice President and Chief Medical Officer. This agreement provides for an annual salary of $210,000 which shall increase at the discretion of the Company’s Compensation Committee. In addition, the offer letter provides for a discretionary bonus of up to 35% of base salary for all years. In addition, on January 23, 2014, the Company’s Board of Directors granted a qualified stock option to its VP – Commercial Operations under the Company’s 2013 Equity Incentive Plan to purchase 125,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.76 per share. These options vest 25% per year over four years, with accelerated vesting of 25% upon a termination without cause or for good reason. | |
On March 12, 2014, the Company signed an SOW with BRNI to continue pre-clinical activities relating to the commercialization of the Company’s therapeutic product. The Company is obligated to pay BRNI a total of $465,000. Of this amount, the Company has paid $358,470 (see “Related Party Transactions” above), the remaining $106,530 to be paid upon the completion, by BRNI, of certain activities relating to: transferring test materials; bio-analytical testing; contracting with a suitable contract research organization; completion of testing assays, and; finalizing a clinical study protocol. | |
After December 31, 2013, 149,000 shares of Series A Preferred Stock were converted at the option of their holders into 149,000 shares of common stock. | |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies: (Policies) | 12 Months Ended |
Dec. 31, 2013 | |
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract] | ' |
Development Stage Enterprises Policy [Policy Text Block] | ' |
Development Stage: | |
The Company is considered to be a development stage company, as defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915-10, in that the Company is devoting substantially all of its efforts to establishing a new business where planned principal operations have commenced, but no revenues have been derived from these operations. | |
In addition, the Company’s licensed technology may not be ready for commercialization for several years, if at all. The Company expects to continue to incur losses at least until commercialization, because it anticipates that its expenditures on research and development and administrative activities will significantly exceed any potential revenues during the period. The Company cannot predict when, if ever, it will become profitable. | |
Use of Estimates, Policy [Policy Text Block] | ' |
Use of Estimates: | |
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |
Cash and Cash Equivalents, Policy [Policy Text Block] | ' |
Cash and Cash Equivalents: | |
The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2013, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation. | |
Research and Development Expense, Policy [Policy Text Block] | ' |
Research and Development Costs: | |
All research and development costs, including costs to maintain or expand the patent portfolio which do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2013 and 2012. | |
Income Tax, Policy [Policy Text Block] | ' |
Income Taxes: | |
Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carry forwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carry forwards, which will either be taxable or deductible when the related assets, liabilities or carry forwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. | |
Income Tax Uncertainties, Policy [Policy Text Block] | ' |
Uncertain Tax Positions: | |
The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions. | |
The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through December 31, 2012. The Company has not yet filed tax returns for the year ended December 31, 2013. | |
In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed. | |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | ' |
Risks and Uncertainties: | |
The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation, including but not limited to the United States FDA drug and device approval processes. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks including the potential for business failure | |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' |
Stock Compensation: | |
The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. For all employee stock options, we recognize expense over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. | |
Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model. | |
Earnings Per Share, Policy [Policy Text Block] | ' |
Earnings per Share: | |
Basic earnings per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants and convertible stock, subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of December 31, 2013 and 2012. At December 31, 2013 and 2012, respectively, approximately 31.5 million and 0 shares underlying the convertible debentures, options and warrants were anti-dilutive. | |
Stock_Options_Tables
Stock Options: (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] | ' | |||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||
A summary of the Company’s stock option activity from inception to December 31, 2013 is as follows: | ||||||||
Weighted-Average | ||||||||
Options Outstanding | Exercise Price | |||||||
Outstanding at December 31, 2012 | 0 | |||||||
Options granted | 6,489,404 | $ | 1.47 | |||||
Options forfeited | -239,452 | $ | -1 | |||||
Options exercised | 0 | 0 | ||||||
Outstanding at December 31, 2013 | 6,249,952 | $ | 1.48 | |||||
Options exercisable | 3,764,733 | $ | 1.71 | |||||
Common_and_Preferred_Stock_Res1
Common and Preferred Stock Reserved for Future Issuances: (Tables) | 12 Months Ended | |||||
Dec. 31, 2013 | ||||||
Common And Preferred Stock Reserved For Future Issuances [Abstract] | ' | |||||
Schedule of Guarantor Obligations [Table Text Block] | ' | |||||
Common stock and preferred stock reserved for future issuances consisted of the following at December 31, 2013: | ||||||
Common Stock | Preferred Stock | |||||
Reserved | Reserved | |||||
Common stock warrants outstanding | 900,000 | |||||
Preferred stock warrants outstanding | 1,217,000 | 1,217,000 | ||||
Common stock options outstanding | 6,249,952 | 0 | ||||
Conversion of Series A preferred stock | 23,000,000 | 0 | ||||
Total | 31,366,952 | 1,217,000 | ||||
Organization_and_Nature_of_Pla1
Organization and Nature of Planned Business: (Details Textual) | 12 Months Ended | 1 Months Ended | ||
Dec. 31, 2013 | Feb. 28, 2013 | Dec. 31, 2012 | Feb. 28, 2013 | |
NBI [Member] | ||||
Organization And Nature Of Planned Business [Line Items] | ' | ' | ' | ' |
Business Acquisition Exchange Ratio | '1:1 | ' | ' | ' |
Stockholders Equity Note, Stock Split | ' | ' | ' | 'NBI effected a stock split in which each of the 1,000 issued and outstanding shares of its common stock was converted into 19,000 shares of its common stock. |
Common Stock, Shares, Issued | 21,740,006 | 19,000,000 | 21,690,406 | 1,000 |
Common Stock, Shares, Outstanding | 21,740,006 | ' | 21,690,406 | 1,000 |
Conversion of Stock, Shares Issued | ' | ' | ' | 19,000 |
Contractual_Commitments_Detail
Contractual Commitments: (Details Textual) (USD $) | 2 Months Ended | 12 Months Ended | 1 Months Ended | ||||||
Feb. 28, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Feb. 25, 2013 | Feb. 28, 2013 | Jun. 30, 2013 | |
Employment Contracts [Member] | Employment Contracts [Member] | Employment Contracts [Member] | Employment Contracts [Member] | Independent Contractor Agreement [Member] | Ramat [Member] | Medical Cash Management Solutions, LLC [Member] | |||
Qualifed Stock Option [Member] | Maximum [Member] | Minimum [Member] | |||||||
Contractual Commitments And Contingencies [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
General Contractor Costs | $20,833 | ' | ' | ' | ' | ' | ' | ' | ' |
Annual Salary Providing Under Agreement | ' | ' | ' | ' | ' | ' | 250,000 | ' | ' |
Annual Bonus Providing Under Agreement | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' |
Increasing Decrease In Annual Salary | ' | ' | ' | ' | ' | ' | 300,000 | ' | ' |
Increasing Decrease In Annual bonus | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' |
Technology Services Costs | ' | ' | ' | ' | ' | ' | ' | 50,000 | 20,000 |
Service Cost Paid Under Installment | ' | ' | ' | ' | ' | ' | ' | 4,167 | ' |
Stock Option Entitled To Related Party | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' |
Stock Option Entitled To Related Party Purchase Price Per Share | ' | ' | $1 | ' | ' | ' | ' | $1 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage | ' | ' | ' | ' | ' | ' | ' | 20.00% | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | ' | ' | ' | ' | '4 years | ' |
Bonus | ' | ' | ' | ' | 50,000 | 35,000 | ' | ' | ' |
Targeted Bonus Percentage Of Base Salary | ' | ' | 50.00% | ' | ' | ' | ' | ' | ' |
Officers Compensation | ' | ' | ' | ' | $275,000 | $240,000 | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | ' | ' | ' | 25.00% | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | ' | ' | 650,000 | ' | ' | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | ' | ' | ' | '4 years | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | ' | '9 years 7 months 20 days | ' | '10 years | ' | ' | ' | ' | ' |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies: (Details Textual) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Summary of Significant Accounting Policies [Line Items] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 31,500,000 | 0 |
Related_Party_Transactions_Det
Related Party Transactions: (Details Textual) (USD $) | 1 Months Ended | 12 Months Ended | 1 Months Ended | 2 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 2 Months Ended | |||||||||||
Aug. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Aug. 31, 2013 | Mar. 31, 2013 | Feb. 28, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Oct. 04, 2013 | Feb. 28, 2013 | Dec. 31, 2013 | Feb. 28, 2013 | Dec. 31, 2013 | |
Subsequent Event [Member] | Fixed Research Fee [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Services Reimbursement [Member] | Statement Of Work Agreement [Member] | Statement Of Work Agreement [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member] | President [Member] | Director [Member] | |||
Subsequent Event [Member] | Subsequent Event [Member] | Minimum [Member] | Maximum [Member] | Monthly Installment [Member] | Technology License And Services Agreement [Member] | Fixed Research Fee [Member] | |||||||||||||
Minimum [Member] | |||||||||||||||||||
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Professional Fees | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $41,667 | ' |
Equity Method Investment, Ownership Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 41.50% |
Proceeds from Issuance of Preferred Stock and Preference Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000,000 | 25,000,000 | ' | ' |
Technology Services Costs | ' | ' | ' | ' | ' | ' | ' | ' | 1,198,696 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Additional Technology Services Costs | ' | ' | ' | ' | ' | ' | 266,666 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Research and Development Expense, Total | ' | ' | 1,000,000 | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Research Fee Subsequent Terms | ' | '5 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Royalties Percentage | ' | ' | ' | ' | ' | ' | ' | 5.00% | ' | ' | 2.00% | 5.00% | ' | ' | ' | ' | ' | ' | ' |
Royalty Expense | ' | ' | ' | ' | ' | 409,549 | ' | ' | ' | 60,349 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Royalty Prepaid | ' | ' | ' | ' | 520,252 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Compensation Related To Product development And Negotiation Of Agreements, Per Month | 9,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments to Acquire Productive Assets, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,645,470 | 137,123 | ' | ' | ' | ' | ' |
Development Cost Payment Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '12 months | ' | ' | ' | ' | ' |
Additional Payments To Acquire Productive Assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 877,300 | ' | ' | ' | ' | ' | ' |
Payment For Personnel And Research Services | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 251,939 | ' | ' | ' | ' | ' | ' |
Prepaid Royalties | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $48,600 | ' | ' | ' | ' |
Income_Taxes_Details_Textual
Income Taxes: (Details Textual) (USD $) | 14 Months Ended |
Dec. 31, 2013 | |
Income Tax Expenses Benefit [Line Items] | ' |
Deferred Tax Assets, Gross, Total | $3,069,247 |
Operating Income (Loss) | $9,027,197 |
Common_Stock_Details_Textual
Common Stock: (Details Textual) (USD $) | Dec. 31, 2013 | Aug. 21, 2013 | Aug. 05, 2013 | Feb. 28, 2013 | Dec. 31, 2012 | Aug. 05, 2013 | Feb. 28, 2013 | Aug. 21, 2013 | Aug. 21, 2013 | Aug. 05, 2013 |
Blue Flash Common Stock [Member] | NBI [Member] | NBI [Member] | NBI [Member] | Blue Flash [Member] | ||||||
Maximum [Member] | Minimum [Member] | |||||||||
Class of Stock [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Shares Authorized | 300,000,000 | ' | 300,000,000 | ' | 300,000,000 | ' | 45,000,000 | 57,000,000 | 45,000,000 | ' |
Common Stock, Par or Stated Value Per Share | $0.00 | ' | ' | ' | $0.00 | $0.00 | $0.01 | ' | ' | ' |
Common Stock, Shares, Issued | 21,740,006 | ' | ' | 19,000,000 | 21,690,406 | ' | 1,000 | ' | ' | ' |
Preferred Stock, Shares Authorized | 50,000,000 | 50,000,000 | 50,000,000 | ' | 50,000,000 | ' | ' | ' | ' | ' |
Preferred Stock, Par or Stated Value Per Share | $0.00 | ' | $0.00 | ' | $0.00 | ' | ' | ' | ' | ' |
Common Stock, Shares, Outstanding | 21,740,006 | ' | ' | ' | 21,690,406 | ' | 1,000 | ' | ' | 100 |
Business Acquisition, Equity Interest Issued or Issuable, Description | ' | ' | ' | ' | ' | 'each share of common stock of BlueFlash, $0.0001 par value per share (“BlueFlash Common Stock”) was automatically converted into 2.242 shares of Neurotrope Common Stock. | ' | ' | ' | ' |
Surrender Of Share | 20,178,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred_Stock_Details_Textua
Preferred Stock: (Details Textual) (USD $) | 12 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | ||||||||||||||||||
Dec. 31, 2013 | Aug. 21, 2013 | Aug. 05, 2013 | 31-May-13 | Dec. 31, 2012 | Dec. 31, 2013 | 31-May-13 | Feb. 28, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Feb. 28, 2013 | Oct. 30, 2013 | Dec. 31, 2013 | Aug. 23, 2013 | 31-May-13 | Aug. 31, 2013 | 30-May-13 | Aug. 23, 2013 | 17-May-13 | Dec. 31, 2013 | Oct. 04, 2013 | Oct. 04, 2013 | |
Common Stock [Member] | Common Stock [Member] | NBI [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | ||||||
NBI [Member] | NBI [Member] | NBI [Member] | NBI [Member] | NBI [Member] | NBI [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | ||||||||||||||
NBI [Member] | ||||||||||||||||||||||
Class of Stock [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Shares Issued | 23,000,000 | ' | ' | ' | 0 | ' | ' | ' | ' | ' | 9,073,300 | ' | ' | ' | ' | ' | ' | 11,533,375 | 1,313,325 | ' | ' | 1,080,000 |
Preferred Stock, Par or Stated Value Per Share | $0.00 | ' | $0.00 | ' | $0.00 | ' | ' | ' | ' | ' | $1 | ' | ' | ' | ' | ' | ' | $1 | $1 | ' | ' | $1 |
Preferred Stock, Value, Issued | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $9,073,300 | ' | ' | ' | ' | ' | ' | $11,533,375 | $1,313,325 | ' | ' | $1,080,000 |
Payment To Private Placement Agent Description | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'a cash fee equal to the sum of (a) 10% of the proceeds received from purchasers sourced by Allied Beacon Partners, Inc. and (b) 5% of the proceeds received from purchasers sourced by the Company. No fee was payable on proceeds received from purchasers who were already stockholders of the Company. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fees and Commissions | ' | ' | ' | ' | ' | ' | ' | ' | ' | 882,330 | ' | ' | ' | ' | ' | 1,103,338 | 131,332 | ' | ' | ' | ' | ' |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | ' | ' | ' | 988,663 | ' | ' | 480,320 | ' | ' | ' | ' | ' | ' | ' | 508,343 | ' | ' | ' | ' | 900,000 | 108,000 | ' |
Percentage of cash commission agreed to pay placement agent | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants issued to placement agent description | '(a) for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 2.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 10% of the number of shares of Series A preferred stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the Agent Warrants). As a result of the foregoing aggregate placements, the placement agent was issued Agent Warrants to purchase 900,000 shares of the Companys Common Stock and 1,325,000 shares of the Companys Series A preferred stock. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fees and Commissions, Transfer Agent | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 108,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Dividend Rate, Per-Dollar-Amount | $0.08 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Common Stock, Par or Stated Value Per Share | $0.00 | ' | ' | ' | $0.00 | $0.01 | ' | $0.01 | ' | ' | ' | ' | $1 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Sale of Stock, Price Per Share | $5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of Stock, Amount Issued | $30,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Shares Authorized | 50,000,000 | 50,000,000 | 50,000,000 | ' | 50,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Exercise Price of Warrants or Rights | ' | ' | ' | ' | ' | ' | 0.01 | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Liquidation Preference Per Share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1 | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Shares Outstanding | 23,000,000 | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 21,920,000 | ' | ' | ' | ' |
Warrants_Details_Textual
Warrants: (Details Textual) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Class of Warrant or Right [Line Items] | ' | ' |
Warrant Issued | 2,225,000 | ' |
Fair Value Of Warrant | 2,020,813 | ' |
Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | '9 years 8 months 5 days | ' |
Preferred Stock Value Decreased | $806,428 | ' |
Options forfeited | $1,214,385 | ' |
Warrants Not Settleable in Cash [Member] | ' | ' |
Class of Warrant or Right [Line Items] | ' | ' |
Warrant Issued | 2,225,000 | ' |
Fair Value Of Warrant | 2,020,813 | ' |
Fair Value Assumptions, Risk Free Interest Rate | 2.70% | ' |
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ' |
Fair Value Assumptions, Expected Term | '10 years | ' |
Fair Value Assumptions, Expected Volatility Rate | 105.50% | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | '10 years | ' |
Common Stock [Member] | ' | ' |
Class of Warrant or Right [Line Items] | ' | ' |
Warrant Issued | 900,000 | ' |
Common Stock, Par or Stated Value Per Share | $0.01 | ' |
Series A Preferred Stock [Member] | ' | ' |
Class of Warrant or Right [Line Items] | ' | ' |
Warrant Issued | 1,325,000 | ' |
Common Stock, Par or Stated Value Per Share | $1 | ' |
Stock_Options_Details
Stock Options: (Details) (USD $) | 12 Months Ended |
Dec. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding at December 31, 2012 | 0 |
Options granted | 6,489,404 |
Options forfeited | -239,452 |
Options exercised | 0 |
Outstanding at December 31, 2013 | 6,249,952 |
Options exercisable | 3,764,733 |
Weighted-Average Exercise Price, Options granted | $1.47 |
Weighted-Average Exercise Price, Options canceled | ($1) |
Weighted-Average Exercise Price, Options exercised | $0 |
Weighted-Average Exercise Price, Outstanding at December 31, 2013 | $1.48 |
Weighted-Average Exercise Price, Options exercisable | $1.71 |
Stock_Options_Details_Textual
Stock Options: (Details Textual) (USD $) | 2 Months Ended | 12 Months Ended | 14 Months Ended |
Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | ' | $1.71 | $1.71 |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | ' | 0.00% | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | ' | 104.70% | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | ' | 2.71% | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | ' | $0.84 | ' |
Share-based Compensation, Total | $0 | $3,122,944 | $3,122,944 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | ' | '9 years 7 months 20 days | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | ' | '9 years 8 months 5 days | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | 0 | 2,600,000 | 2,600,000 |
Employee Stock Option [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation, Total | ' | 3,100,000 | 3,100,000 |
Research and Development Expense, Total | ' | 200,000 | ' |
Allocated Share-based Compensation Expense | ' | $2,900,000 | ' |
Equity Incentive Plan 2013 [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | ' | 7,000,000 | 7,000,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | 5,154,404 | ' |
Equity Incentive Plan 2013 [Member] | Founding Stock Holder [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | 3,500,000 | ' |
Equity Incentive Plan 2013 [Member] | Consultant One [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | 54,404 | ' |
Equity Incentive Plan 2013 [Member] | Founding Stock Holder and Consultant One [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | ' | $1.75 | $1.75 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | ' | 100.00% | ' |
Equity Incentive Plan 2013 [Member] | Consultant Two [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | 250,000 | ' |
Equity Incentive Plan 2013 [Member] | Director And Consultant Two [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | '10 years | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | ' | $1 | $1 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | ' | 20.00% | ' |
Number of Director | ' | 4 | 4 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | ' | '5 years | ' |
Equity Incentive Plan 2013 [Member] | Consultant Three [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | 300,000 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | '10 years | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | ' | $1 | $1 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | ' | 20.00% | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | ' | '4 years | ' |
Equity Incentive Plan 2013 [Member] | Director [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | 1,050,000 | ' |
Common_and_Preferred_Stock_Res2
Common and Preferred Stock Reserved for Future Issuances: (Details) | Dec. 31, 2013 |
Class of Stock [Line Items] | ' |
Common Stock Reserved | 31,366,952 |
Preferred Stock Reserved | 1,217,000 |
Common Stock Warrant Outstanding [Member] | ' |
Class of Stock [Line Items] | ' |
Common Stock Reserved | 900,000 |
Preferred Stock Warrant Outstanding [Member] | ' |
Class of Stock [Line Items] | ' |
Common Stock Reserved | 1,217,000 |
Preferred Stock Reserved | 1,217,000 |
Common Stock Option Outstanding [Member] | ' |
Class of Stock [Line Items] | ' |
Common Stock Reserved | 6,249,952 |
Preferred Stock Reserved | 0 |
Series A Preferred Stock [Member] | ' |
Class of Stock [Line Items] | ' |
Common Stock Reserved | 23,000,000 |
Preferred Stock Reserved | 0 |
Subsequent_Events_Details_Text
Subsequent Events: (Details Textual) (USD $) | 12 Months Ended |
Dec. 31, 2013 | |
Subsequent Event [Line Items] | ' |
Sale of Stock, Price Per Share | $5 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | '9 years 7 months 20 days |
Employment Contracts [Member] | ' |
Subsequent Event [Line Items] | ' |
Targeted Bonus Percentage Of Base Salary | 50.00% |
Employment Contracts [Member] | Qualifed Stock Option [Member] | ' |
Subsequent Event [Line Items] | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 650,000 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | '4 years |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | '10 years |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | 25.00% |
Employment Contracts [Member] | Minimum [Member] | ' |
Subsequent Event [Line Items] | ' |
Officers Compensation | $240,000 |
Employment Contracts [Member] | Maximum [Member] | ' |
Subsequent Event [Line Items] | ' |
Officers Compensation | 275,000 |
Subsequent Event [Member] | ' |
Subsequent Event [Line Items] | ' |
Contractual Obligation, Total | 465,000 |
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year | 106,530 |
Repayments Of Obligation Debt | 358,470 |
Subsequent Event [Member] | Common Stock [Member] | ' |
Subsequent Event [Line Items] | ' |
Conversion of Stock, Shares Issued | 149,000 |
Subsequent Event [Member] | NBIs Vice President - Regulatory Affairs [Member] | ' |
Subsequent Event [Line Items] | ' |
Sale of Stock, Price Per Share | $1.76 |
Targeted Bonus Percentage Of Base Salary | 20.00% |
Officers Compensation | 195,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 75,000 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | '5 years |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | '10 years |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | 20.00% |
Subsequent Event [Member] | NBIs Vice President - Commercial Operations [Member] | ' |
Subsequent Event [Line Items] | ' |
Sale of Stock, Price Per Share | $1.76 |
Targeted Bonus Percentage Of Base Salary | 35.00% |
Officers Compensation | 210,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 100,000 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | '5 years |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | '10 years |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | 20.00% |
Subsequent Event [Member] | NBIs Vice President - Chief Medical Officer [Member] | ' |
Subsequent Event [Line Items] | ' |
Sale of Stock, Price Per Share | $1.76 |
Targeted Bonus Percentage Of Base Salary | 35.00% |
Officers Compensation | $210,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 125,000 |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period | '4 years |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term | '10 years |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage | 25.00% |
Series A Preferred Stock [Member] | Subsequent Event [Member] | ' |
Subsequent Event [Line Items] | ' |
Conversion of Stock, Shares Converted | 149,000 |